Analyst Price Targets — NBRV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2023 1:05 pm | Carl Byrnes | Northland Securities | $1.00 | $1.33 | TheFly | Nabriva Therapeutics downgraded to Underperform from Outperform at Northland |
Latest News for NBRV
Profitability This table compares Aadi Bioscience and Nabriva Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Nabriva Therapeutics -148.11% -365.53% -135.81% Institutional and Insider Ownership 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics
Volatility and Risk Virpax Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Insider and Institutional Ownership 32.2% of Virpax Pharmaceuticals shares are held
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NBRV.
U.S. House Trading
No House trades found for NBRV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.